Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Video: Sitting Down With… Delara Motlagh
Fujifilm Cellular Dynamics’ Delara Motlagh discusses her path into cell and gene therapy, the challenges of scaling manufacturing, and the potential of iPSC technologies
Clinical Scorecard: Video: Sitting Down With… Delara Motlagh
At a Glance
Category
Detail
Condition
Cell and gene therapy, including induced pluripotent stem cell (iPSC) research and therapeutics
Key Mechanisms
The interview discusses iPSCs and the manufacturing challenges involved in advanced therapies; specific biological mechanisms are not described.
Target Population
Not specified; the interview concerns cell and gene therapy research, therapeutics, and manufacturing.
Care Setting
Industry and research context, including cell and gene therapy manufacturing, contract development and manufacturing organizations (CDMOs), and technology providers.
Key Highlights
Delara Motlagh discusses her career and leadership experiences over more than two decades in cell and gene therapy.
The interview addresses approaches to solving complex manufacturing problems.
Motlagh discusses the promise of iPSCs in research and therapeutics.
The conversation considers how CDMOs and technology providers can help make advanced therapies more accessible.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
No patient population or prescribing information is provided.
The interview discusses iPSC research and therapeutics but provides no specific treatment or prescribing guidance.
